|
[posting]56036529[/posting]Im letzten Monat gab es mehrere Veröffentlichungen zu Mesupron von dem Partner Redhill. Webseite: https://www.redhillbio.com/RedHill/index.asp?DBID=1&LNGID=1 RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers 18 September, 2017 TEL-AVIV, Israel / RALEIGH, NC, September 18, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering the use of two of RedHill’s Phase II-stage proprietary investigational compounds, YELIVA\u00ae and MESUPRON in combination with a known antibiotic. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB… [/https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB… RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 20 October, 2017 RedHill to benefit from various incentives to develop MESUPRON (upamostat) for the adjuvant treatment of pancreatic cancer, including a seven-year marketing exclusivity period for the indication, if approved MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis Pancreatic cancer is the third leading cause of cancer mortality in the U.S. and is characterized as a disease with a very high unmet medical need The 2017 Worldwide sales of pancreatic cancer therapies are estimated to reach approximately $1.6 billion Recently identified high-affinity molecular targets suggest additional applications in inflammatory gastrointestinal diseases TEL-AVIV, Israel / RALEIGH, NC, October 20, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted MESUPRON (upamostat) Orphan Drug designation for the adjuvant treatment of pancreatic cancer. The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication, including tax credits for qualified clinical testing, waiver of a prescription drug user fee (PDUFA fee) upon submission of a potential marketing application and, if approved, a seven-year marketing exclusivity period. MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis. MESUPRON presents a new, non-cytotoxic approach to cancer therapy. MESUPRON has undergone several Phase I studies and two Phase II proof-of-concept studies. RedHill recently announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering the use of MESUPRON and RedHill’s Phase II-stage investigational compound, YELIVA\u00ae, in combination with a known antibiotic, for hard-to-treat cancers. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB…" target="_blank" rel="nofollow ugc noopener"> RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 19 October, 2017 TEL-AVIV, Israel / RALEIGH, NC, October 19, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced a planned poster presentation relating to the active metabolite of MESUPRON, WX-UK1, at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, on Sunday, October 29, 2017, from 12:30 - 4:00 PM, at the Pennsylvania Convention Center in Philadelphia, PA. MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis. MESUPRON presents a new, non-cytotoxic approach to cancer therapy and potentially to additional inflammatory gastrointestinal diseases, such as diarrhea-predominant irritable bowel syndrome (IBS-D), pancreatitis and inflammatory bowel disease (IBD). https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB… RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 20 October, 2017 RedHill to benefit from various incentives to develop MESUPRON (upamostat) for the adjuvant treatment of pancreatic cancer, including a seven-year marketing exclusivity period for the indication, if approved MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis Pancreatic cancer is the third leading cause of cancer mortality in the U.S. and is characterized as a disease with a very high unmet medical need The 2017 Worldwide sales of pancreatic cancer therapies are estimated to reach approximately $1.6 billion Recently identified high-affinity molecular targets suggest additional applications in inflammatory gastrointestinal diseases TEL-AVIV, Israel / RALEIGH, NC, October 20, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted MESUPRON (upamostat) Orphan Drug designation for the adjuvant treatment of pancreatic cancer. The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication, including tax credits for qualified clinical testing, waiver of a prescription drug user fee (PDUFA fee) upon submission of a potential marketing application and, if approved, a seven-year marketing exclusivity period. MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis. MESUPRON presents a new, non-cytotoxic approach to cancer therapy. MESUPRON has undergone several Phase I studies and two Phase II proof-of-concept studies. RedHill recently announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering the use of MESUPRON and RedHill’s Phase II-stage investigational compound, YELIVA\u00ae, in combination with a known antibiotic, for hard-to-treat cancers. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB…" target="_blank" rel="nofollow ugc noopener">https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB… [/https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB… RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 20 October, 2017 RedHill to benefit from various incentives to develop MESUPRON (upamostat) for the adjuvant treatment of pancreatic cancer, including a seven-year marketing exclusivity period for the indication, if approved MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis Pancreatic cancer is the third leading cause of cancer mortality in the U.S. and is characterized as a disease with a very high unmet medical need The 2017 Worldwide sales of pancreatic cancer therapies are estimated to reach approximately $1.6 billion Recently identified high-affinity molecular targets suggest additional applications in inflammatory gastrointestinal diseases TEL-AVIV, Israel / RALEIGH, NC, October 20, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted MESUPRON (upamostat) Orphan Drug designation for the adjuvant treatment of pancreatic cancer. The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication, including tax credits for qualified clinical testing, waiver of a prescription drug user fee (PDUFA fee) upon submission of a potential marketing application and, if approved, a seven-year marketing exclusivity period. MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis. MESUPRON presents a new, non-cytotoxic approach to cancer therapy. MESUPRON has undergone several Phase I studies and two Phase II proof-of-concept studies. RedHill recently announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering the use of MESUPRON and RedHill’s Phase II-stage investigational compound, YELIVA\u00ae, in combination with a known antibiotic, for hard-to-treat cancers. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB…" target="_blank" rel="nofollow ugc noopener"> RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 19 October, 2017 TEL-AVIV, Israel / RALEIGH, NC, October 19, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced a planned poster presentation relating to the active metabolite of MESUPRON, WX-UK1, at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, on Sunday, October 29, 2017, from 12:30 - 4:00 PM, at the Pennsylvania Convention Center in Philadelphia, PA. MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis. MESUPRON presents a new, non-cytotoxic approach to cancer therapy and potentially to additional inflammatory gastrointestinal diseases, such as diarrhea-predominant irritable bowel syndrome (IBS-D), pancreatitis and inflammatory bowel disease (IBD). https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB… RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 20 October, 2017 RedHill to benefit from various incentives to develop MESUPRON (upamostat) for the adjuvant treatment of pancreatic cancer, including a seven-year marketing exclusivity period for the indication, if approved MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis Pancreatic cancer is the third leading cause of cancer mortality in the U.S. and is characterized as a disease with a very high unmet medical need The 2017 Worldwide sales of pancreatic cancer therapies are estimated to reach approximately $1.6 billion Recently identified high-affinity molecular targets suggest additional applications in inflammatory gastrointestinal diseases TEL-AVIV, Israel / RALEIGH, NC, October 20, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted MESUPRON (upamostat) Orphan Drug designation for the adjuvant treatment of pancreatic cancer. The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication, including tax credits for qualified clinical testing, waiver of a prescription drug user fee (PDUFA fee) upon submission of a potential marketing application and, if approved, a seven-year marketing exclusivity period. MESUPRON is a proprietary, first-in-class, orally-administered protease inhibitor, with several potential mechanisms of action to inhibit tumor invasion and metastasis. MESUPRON presents a new, non-cytotoxic approach to cancer therapy. MESUPRON has undergone several Phase I studies and two Phase II proof-of-concept studies. RedHill recently announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering the use of MESUPRON and RedHill’s Phase II-stage investigational compound, YELIVA\u00ae, in combination with a known antibiotic, for hard-to-treat cancers. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DB… |
|
| aus der Diskussion: | Heidelberg Pharma AG |
| Autor (Datum des Eintrages): | BICYPAPA (27.10.17 07:27:30) |
| Beitrag: | 2 von 5,204 (ID:56038383) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |